TWI620576B - Oral composition - Google Patents

Oral composition Download PDF

Info

Publication number
TWI620576B
TWI620576B TW102132187A TW102132187A TWI620576B TW I620576 B TWI620576 B TW I620576B TW 102132187 A TW102132187 A TW 102132187A TW 102132187 A TW102132187 A TW 102132187A TW I620576 B TWI620576 B TW I620576B
Authority
TW
Taiwan
Prior art keywords
cold water
biofilm
water extract
biofilm formation
extract
Prior art date
Application number
TW102132187A
Other languages
Chinese (zh)
Other versions
TW201431565A (en
Inventor
Shota Mohri
Takanori Tsugane
Yoji Saeki
Original Assignee
Lotte Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lotte Co Ltd filed Critical Lotte Co Ltd
Publication of TW201431565A publication Critical patent/TW201431565A/en
Application granted granted Critical
Publication of TWI620576B publication Critical patent/TWI620576B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

本發明係提供與已存在的抗菌劑等比較,具有耐性菌出現風險低等優點之嶄新觀點之牙周病預防劑。含有水菜冷水萃取物之具有生物薄膜形成抑制作用之口腔用組成物。 The present invention provides a periodontal disease preventive agent with a novel viewpoint compared with existing antibacterial agents and the like, which has the advantages of low risk of occurrence of resistant bacteria and the like. Oral composition having a biofilm formation inhibitory effect containing cold water extract of watercress.

Description

口腔用組成物 Oral composition

本發明係關於對口腔疾病原因之口腔生物薄膜之牙周病改善效果優異之口腔組成物。 The present invention relates to an oral composition having an excellent periodontal disease improving effect on an oral biofilm that causes oral diseases.

所謂牙周病係見於牙周組織之疾病群總稱,狹義上係相當於牙齦炎、牙周炎及咬合性外傷之疾病。牙周病係牙齒的牙菌斑為主要原因所引起之口腔內感染症。人的口腔內存在700種以上的細菌,健康的口腔內,鏈球菌(Streptococcus)屬或放線菌(Actinomyces)屬之初期附著菌附著於牙面。其中之內氏放線菌(Actinomyces naeslundii)被稱為是出血性牙齦炎原因菌,初期附著之A.naeslundii形成生物薄膜,形成牙菌斑,使牙齦發生炎症。報告揭示放線菌(Actinomyces)所引起之牙齦炎症係菌體膜上的脂蛋白質,經由牙齦上皮細胞或巨噬細胞之TLR2,使產生IL-8或TNF-α所引起。若牙齦引起炎症時,形成牙周囊袋,並且伴隨著出血或牙齦溝滲出液的滲出,已知作為牙周病原性細菌之Porphyromonas gingivalis或Aggregatibacter actinomycetemcomitans、Treponema denticola等整備定住於牙周囊袋的環境。另外,A.naeslundii不僅附著於牙面,與許多的口腔內細菌共同凝聚,成為牙周病原性細菌定住於牙菌斑的支架。由此等事實,因為A.naeslundii使初期牙菌斑衍變成後期牙菌斑(牙周病生物薄膜),所以作為牙周病發病相關重要細菌,近年來受到矚目。 The so-called periodontal disease is a group of diseases found in periodontal tissues. In the narrow sense, it is equivalent to gingivitis, periodontitis, and occlusive trauma. Periodontal disease is an oral infection caused by dental plaque as the main cause. There are more than 700 kinds of bacteria in the human oral cavity. In healthy oral cavity, the initial attached bacteria of the genus Streptococcus or Actinomyces belong to the tooth surface. Among them, Actinomyces naeslundii is known as the cause of hemorrhagic gingivitis, and A.naeslundii, which is initially attached, forms a biofilm, forms plaque, and causes inflammation of the gums. The report revealed that lipoproteins on the bacterial membrane of the gingival inflammation system caused by Actinomyces are caused by the production of IL-8 or TNF-α through the TLR2 of gingival epithelial cells or macrophages. If the gums cause inflammation, periodontal sacs are formed and accompanied by bleeding or exudate of gingival sulcus exudates, known as Porphyromonas gingivalis or Aggregatibacter actinomycetemcomitans, Treponema Denticola and others are settled in the environment of periodontal sac. In addition, A.naeslundii not only adheres to the tooth surface, but also co-aggregates with many oral bacteria, becoming a scaffold for periodontal pathogenic bacteria to settle on plaque. From these facts, A. naeslundii has attracted attention in recent years as an important bacterium related to the occurrence of periodontal disease because plaque in the early stage is transformed into a plaque in the late stage (biofilm of periodontal disease).

傳統的牙周病預防係將P.gingivalis等之牙周病原性細菌殺菌,抑制牙周病之想法為主流,但因為牙周病原性細菌係與生物薄膜共存於牙周囊袋的深部,所以抗菌物質難以滲入,大多不能得到預期的效果。 Traditional periodontal disease prevention systems have sterilized periodontal pathogenic bacteria such as P.gingivalis and suppressed periodontal disease. However, because periodontal pathogenic bacteria and biofilms coexist deep in the periodontal sac, Antibacterial substances are difficult to penetrate, and most of them fail to obtain the desired effect.

為改善此點,專利文獻1揭示藉由摻混(A)N-醯基肌胺酸或其鹽、及(B)苯甲基異硫氰酸酯,而且(A)/(B)之質量比為0.5~20,顯示口腔生物薄膜抗菌效果及牙齦炎改善效果。然而,於專利文獻1中,耐性菌出現的危險度依然高。 In order to improve this, Patent Document 1 discloses that by mixing (A) N-fluorenyl sarcosinic acid or a salt thereof and (B) benzyl isothiocyanate, the quality of (A) / (B) The ratio is 0.5 to 20, showing the antibacterial effect of the oral biofilm and the gingivitis improvement effect. However, in Patent Document 1, the risk of occurrence of resistant bacteria is still high.

因為牙周病係由牙齦炎發病惡化,所以預防牙齦炎可更有效地預防牙周病。因此,抑制A.naeslundii形成生物薄膜之素材,可期待有效的牙周病預防效果。 Because periodontal disease is exacerbated by gingivitis, preventing gingivitis can prevent periodontal disease more effectively. Therefore, an effective periodontal disease prevention effect can be expected by inhibiting A.naeslundii from forming a biofilm material.

本發明者等係確認A.naeslundii形成生物薄膜係由酸壓力所促進的,確認水菜或小松菜等5種十字花科植物與冰花的萃取物使A.naeslundii之酸衍生性生物薄膜的形成量低至50~90%的活性(專利文獻2)。 The present inventors confirmed that the formation of A.naeslundii biofilm was promoted by acid pressure, and confirmed that the extracts of five cruciferous plants such as Brassica chinensis or Komatsuki and ice flowers reduced the amount of acid-derived biofilms of A.naeslundii. To 50 to 90% of activity (Patent Document 2).

本申請書係以認為有生物薄膜形成抑制活性的植物萃取物中,活性最高,且容易取得的水菜(水菜,Brassica rapa var.nipposinica)為候補素材,詳細地檢討詳細的活性評估及其活性成分之性狀鑑定。 In this application, water extract (water dish, Brassica, Brassica rapa var.nipposinica) is a candidate material, and the detailed activity evaluation and the identification of the properties of the active ingredients are reviewed in detail.

〔先前技術文獻〕 [Previous Technical Literature] 〔專利文獻〕 [Patent Literature]

[專利文獻1]特開2008-174542號公報 [Patent Document 1] JP 2008-174542

[專利文獻2]特開2011-196315號說明書 [Patent Document 2] Japanese Patent Application Laid-Open No. 2011-196315

牙周病原性細菌係與生物薄膜共存於牙周囊袋的深部,使用傳統以來之以牙周病原性細菌為標的的抗菌劑之牙周病抑制法,口腔生物薄膜妨礙抗菌劑的滲透,難以產生預期之牙周病抑制效果。並且,使用抗菌劑則耐性菌出現的危險性高,並不適宜。因此,認為比藉由牙周病原性細菌之抗菌劑進行控制,進行控制初期牙周病原性細菌之生物薄膜形成係更安全且效果高之牙周病預防法。 Periodontal pathogenic bacteria coexist with the biofilm in the deep part of the periodontal sac. Using the traditional periodontal disease suppression method with periodontal pathogenic bacteria as the target antibacterial agent, the oral biofilm hinders the penetration of the antibacterial agent. Produces the expected periodontal disease suppression effect. In addition, the use of an antibacterial agent is not suitable because of the high risk of the appearance of resistant bacteria. Therefore, it is considered to be a safer and more effective method for the prevention of periodontal disease than to control the periodontal pathogenic bacteria with an antibacterial agent and to perform a biofilm formation system for controlling periodontal pathogenic bacteria at an early stage.

本發明者等努力研究的結果,發現水菜萃取物對由酸所衍生之Actinomyces naeslundii之薄膜形成具有抑制效果。此抑制效果係萃取溫度為低溫愈高。分離區劃水菜萃取物活性成分的結果,推定活性成分係分子量為10kDa以上之成分,發現活性區劃部份中所含成分之80%以上為蛋白質,完成本發明。另外,因為水菜萃取物不對 A.naeslundii增殖造成影響,所以認為作用機制與抗菌作用是不同的。 As a result of diligent research by the present inventors, it has been found that the watercress extract has an inhibitory effect on the film formation of Actinomyces naeslundii derived from acid. The suppression effect is that the higher the extraction temperature is, the lower the temperature is. As a result of separating the active ingredients of the watercress extract, it is estimated that the active ingredient is a component having a molecular weight of 10 kDa or more, and it is found that more than 80% of the ingredients contained in the active division are proteins, and the present invention has been completed. Also, because the water vegetable extract is wrong A. naeslundii proliferation affects, so it is believed that the mechanism of action is different from the antibacterial effect.

Actinomyces naeslundii係自牙齦炎或根面蛀蝕部位所發現之革蘭氏陽性桿菌,被稱為初期牙周病原性細菌。因為與鏈球菌或牙周病原性細菌共同凝聚,所以為掌握菌叢遷移至牙周病牙菌斑關鍵的細菌,認為控制A.naeslundii與預防牙周病有關聯。本發明者等之研究,確認牙周病原性細菌產生的丁酸等酸增加生物薄膜的形成。 Actinomyces naeslundii is a Gram-positive bacilli found in gingivitis or root erosions, and is known as the primary periodontal pathogenic bacteria. Because it co-aggregates with streptococci or periodontal pathogenic bacteria, in order to grasp the bacteria that are key to the bacterial plaque migration to periodontal disease, controlling A.naeslundii is associated with the prevention of periodontal disease. Studies by the present inventors have confirmed that acids such as butyric acid produced by periodontal pathogenic bacteria increase biofilm formation.

因為本發明之含有水菜萃取物之口腔用組成物明顯地抑制初期牙周病原性細菌之生物薄膜形成,所以有效地作為比抗菌劑更安全且效果高之牙周病預防法。 Since the oral composition containing the hydroponic extract of the present invention significantly inhibits the formation of a biofilm of periodontal pathogenic bacteria at an early stage, it is effective as a method for preventing periodontal disease that is safer and more effective than an antibacterial agent.

用以實施發明之最佳型態 The best form to implement the invention

本申請發明係關於含有水菜萃取物之口腔用組成物。 The present invention relates to a composition for oral cavity containing a hydroponic extract.

進而,本申請發明係關於前述水菜萃取物為冷水萃取物之口腔用組成物。 Furthermore, the present invention relates to an oral composition in which the aforementioned water vegetable extract is a cold water extract.

進而另外,本申請發明係關於含有水菜萃取物之牙周病生物薄膜抑制劑。 Furthermore, the present invention relates to a periodontal disease biofilm inhibitor containing a hydroponic extract.

進而,本申請發明係關於前述水菜萃取物為冷水萃取物之酸衍生生物薄膜抑制劑。 Furthermore, the present invention relates to an acid-derived biofilm inhibitor in which the aforementioned water vegetable extract is a cold water extract.

進而另外,本申請發明係關於由上述口腔用組成物而成之漱口劑、牙膏劑、吸入劑、口含錠劑及食品。 Furthermore, the present invention relates to a mouthwash, a toothpaste, an inhalant, a lozenge, and a food made of the composition for oral cavity.

以下係藉由實施例更具體地說明本發明。另外,本申請發明並非受此等實施例限定者。 Hereinafter, the present invention will be described more specifically with reference to examples. In addition, the invention of this application is not limited by these examples.

[圖1]依萃取溫度不同之生物薄膜形成抑制活性之比較 [Figure 1] Comparison of biofilm formation inhibitory activity by extraction temperature

[圖2]依萃取溫度不同之生物薄膜形成抑制活性之比較 [Figure 2] Comparison of biofilm formation inhibitory activity according to extraction temperature

[圖3]水菜冷水萃取物於羥磷石灰上之生物薄膜形成抑制活性 [Figure 3] Biofilm formation inhibitory activity of cold water extract of hydroponics on hydroxyphosphate lime

[圖4A]口腔內臨床分離株之系統解析 [Figure 4A] Systematic analysis of clinical isolates in the oral cavity

[圖4B]口腔內臨床分離株之系統解析 [Figure 4B] Systematic analysis of clinical isolates in the oral cavity

[圖5]水菜冷水萃取物對臨床分離株之生物薄膜形成抑制活性 [Figure 5] Inhibitory activity of cold water extracts from watercress on biofilm formation in clinical isolates

[圖6]流式處理槽(Flow Cell)中水菜冷水萃取物之生物薄膜形成抑制活性 [Figure 6] Inhibition activity of biofilm formation from cold water extracts of water vegetables in a flow cell

[圖7]藉由共軛焦雷射顯微鏡之生物薄膜觀察圖 [Figure 7] Observation diagram of biofilm by conjugate focus laser microscope

[圖8]水菜冷水萃取物、水菜冷水萃取物藉由透析處理之透析內液、透析外液之生物薄膜形成抑制活性之比較 [Figure 8] Comparison of biofilm formation inhibitory activity of cold water extract and cold water extract of diarrhea by dialysis treatment

[圖9]水菜冷水萃取物透析內液之陰離子交換層析之結果 [Fig. 9] Results of anion exchange chromatography for dialysis of internal fluids of cold water extracts of watercress

[圖10]水菜冷水萃取物透析內液之硫酸銨分離區劃之生物薄膜形成抑制活性 [Fig. 10] Biofilm formation inhibitory activity of ammonium sulfate separation zone for dialysis of internal liquid of cold water extract

[圖11]水菜冷水萃取物透析內液之硫酸銨分離區劃 物之陰離子交換層析之結果 [Figure 11] Ammonium sulfate separation zone for dialysis of internal fluids from cold water extracts of water vegetables Of anion exchange chromatography

[圖12]摻混水菜冷水萃取物口香糖之生物薄膜形成抑制活性 [Figure 12] Inhibition activity of chewing gum mixed with cold water extract of hydroponic vegetables

〔實施例〕 [Example] (實施例1) (Example 1) 水菜萃取物之調製法: Preparation method of water vegetable extract:

購入市售水菜(茨城縣產),以冷凍乾燥調製水菜乾燥葉。將水菜乾燥葉細細粉碎,以相對於1g之此粉碎的水菜乾燥葉,50ml之去離子蒸餾水的比率,以70℃、室溫及4℃進行萃取2小時。將所得之萃取液吸引過濾,以13,000×g.10分鐘離心,將其上清液冷凍乾者作為水菜萃取物,供予試驗。 A commercially available water dish (from Ibaraki Prefecture) was purchased, and dried leaves of the water dish were prepared by freeze-drying. The dried vegetable leaf was finely pulverized, and extracted at 70 ° C, room temperature, and 4 ° C for 2 hours at a ratio of 50 ml of deionized distilled water to 1 g of the crushed dried vegetable leaf. The obtained extract was suction-filtered to 13,000 × g. After centrifugation for 10 minutes, the supernatant was lyophilized as a water vegetable extract for test.

(實施例2) (Example 2)

生物薄膜形成試驗 Biofilm formation test

(實施例2-1) (Example 2-1)

使用96孔微量滴定盤(microtiter plate)之生物薄膜形成 Biofilm formation using a 96-well microtiter plate

將A.naeslundii ATCC19039或Actinomyces spp.臨床分離株,於5ml之Brain Heart Infusion(BHI)液體培養基,於37℃之嫌氣條件下,培養一夜至穩定期 (stationary phase),1,100×g.10分鐘離心集菌。於相同條件,以PBS離心洗淨3次,以PBS調製成O.D.660nm=0.3者作為試驗菌懸浮液,供予試驗系統。 A. naeslundii ATCC19039 or Actinomyces spp. Clinical isolates were cultured in 5 ml of Brain Heart Infusion (BHI) liquid culture medium at 37 ° C. overnight to a stationary phase at 1,100 × g. Centrifuge for 10 minutes to collect bacteria. Under the same conditions, the cells were centrifuged and washed three times with PBS, and those with PBS adjusted to an OD of 660 nm = 0.3 were used as test bacteria suspensions for the test system.

生物薄膜形成係使用96孔微量滴定盤進行。於各孔中添加100μl的添加0.5%蔗糖之2×Trypticase Soy Broth(TSB)培養基、50μl的試驗樣品、20μl的125mM丁酸、20μl的試驗菌懸浮液、10μl的PBS,於37℃,5%CO2之條件下,進行培養16~20小時。 Biofilm formation was performed using a 96-well microtiter plate. Add 100 μl of 2 × Trypticase Soy Broth (TSB) medium with 0.5% sucrose, 50 μl of test sample, 20 μl of 125 mM butyric acid, 20 μl of test bacterial suspension, 10 μl of PBS at 37 ° C, 5% in each well. Under the condition of CO 2 , the culture is performed for 16 to 20 hours.

(實施例2-2) (Example 2-2)

使用96孔微量滴定盤之生物薄膜形成量之定量 Quantification of biofilm formation using a 96-well microtiter plate

傾析依據實施例2-1所培養的培養上清液,以200μl的PBS洗淨各孔後,添加100μl的0.25%之番紅溶液(日水製藥),靜置15分鐘,將生物薄膜染色。傾析番紅溶液後,以去離子蒸餾水洗淨2次,乾燥後,添加100μl的70%酒精,振動30分鐘,使番紅溶出,使用微量盤分析儀,以492nm之吸光度,定量生物薄膜量。 The culture supernatant cultured according to Example 2-1 was decanted, and each well was washed with 200 μl of PBS, and then 100 μl of a 0.25% safranine solution (Nissui Pharmaceutical) was added, and left to stand for 15 minutes to stain the biofilm. . After decanting the safran solution, it was washed twice with deionized distilled water. After drying, 100 μl of 70% alcohol was added and shaken for 30 minutes to dissolve the saffron. Using a microplate analyzer, the absorbance at 492 nm was used to quantify the amount of biofilm. .

依據上述實施例,評估自水菜以70℃、室溫及4℃之各條件下萃取之各水菜萃取物之每重量的比活性時,於4℃之條件下萃取之冷水萃取物之比活性最高(圖1及圖2)。另外,顯示水菜冷水萃取物對A.naeslundii之增殖無影響。 According to the above examples, when the specific activity per weight of each water vegetable extract extracted from water vegetables at 70 ° C, room temperature and 4 ° C was evaluated, the cold water extract extracted at 4 ° C had the highest specific activity. (Figures 1 and 2). In addition, it was shown that the cold water extract of A. napus had no effect on the proliferation of A.naeslundii.

因此,以水菜冷水萃取物作為Actinomyces生物薄膜抑制素材之候補材料,於人口腔內是否有顯示活性的可能 性,進一步進行檢討。 Therefore, is it possible to use cold-water extracts of hydroponics as candidate materials for Actinomyces biofilm inhibition materials to show activity in human oral cavity? And further review.

(實施例2-3) (Example 2-3)

於羥磷石灰(HA)上形成生物薄膜 Biofilm formation on hydroxyphosphate lime (HA)

HA片係使用將牛齒以琺瑯質覆蓋表面,成形成7mm×7mm×1.5mm形狀者。將HA片以殺菌釜滅菌後,藉由PBS於室溫平衡化1小時,將無菌地採取400μl的人唾液,於室溫靜置1小時,使形成薄膜(pellicle),以PBS洗淨後,以5mg/ml之BSA溶液,於室溫阻斷30分鐘者,使用於試驗。 The HA sheet is made of cow teeth covered with enamel to form a 7mm × 7mm × 1.5mm shape. After the HA tablets were sterilized in an autoclave, they were equilibrated with PBS at room temperature for 1 hour, 400 μl of human saliva was taken aseptically, and they were left at room temperature for 1 hour to form a thin film (pellicle). After washing with PBS, A 5 mg / ml BSA solution was blocked at room temperature for 30 minutes, and used in the test.

生物薄膜形成係使用24孔微量滴定盤進行。於各孔中添加400μl的添加0.5%蔗糖之2×TSB培養基、200μl的試驗樣品、80μl的125mM丁酸、80μl的試驗菌懸浮液、40μl的PBS,放置HA片於各孔,依據實施例2-1進行培養。 Biofilm formation was performed using a 24-well microtiter plate. Add 400 μl of 2 × TSB medium with 0.5% sucrose, 200 μl of test sample, 80 μl of 125 mM butyric acid, 80 μl of test bacterial suspension, 40 μl of PBS to each well, and place HA slices in each well, according to Example 2 -1 for culture.

(實施例2-4) (Example 2-4)

HA上之生物薄膜形成量之定量 Quantification of biofilm formation on HA

依據實施例2-3進行培養後,以鎳子取出HA片,浸入PBS一次以洗淨。將洗淨的HA片,放入新孔,添加600μl的番紅溶液,靜置15分鐘,將生物薄膜染色。以鎳子取出HA,以去離子蒸餾水洗淨後,放入新孔,添加600μl的70%乙醇,振動30分鐘,使番紅溶出,將300μl之該溶出液,移到96孔微量滴定盤,依據實施例2-2,定 量生物薄膜量。 After culturing according to Example 2-3, the HA pieces were taken out with nickel seeds and immersed in PBS once to wash. The washed HA sheet was put into a new well, and 600 μl of a saffron solution was added, and left to stand for 15 minutes to stain the biofilm. Take out HA with nickel, wash it with deionized distilled water, put it into a new well, add 600 μl of 70% ethanol, shake for 30 minutes to dissolve saffron, and transfer 300 μl of this eluate to a 96-well microtiter plate. According to Example 2-2, Amount of biofilm.

依據上述實施例,於使形成薄膜(pellicle)之羥磷石灰上,評估水菜冷水萃取物之生物薄膜形成抑制活性的結果如圖3所示。水菜冷水萃取物於羥磷石灰上,與96孔上同樣地顯示A.naeslundii生物薄膜形成抑制活性。 According to the above examples, the results of evaluating the biofilm formation inhibitory activity of cold water extracts of water vegetables on the hydroxyphosphate lime forming a pellicle are shown in FIG. 3. The cold water extract of watercress was on hydroxyphosphate lime, and it showed the inhibitory activity of A.naeslundii biofilm formation in the same way as in 96 wells.

(實施例3) (Example 3)

Actinomyces臨床分離株之分離 Isolation of Actinomyces clinical isolates

(實施例3-1) (Example 3-1)

PCR/Multiplex PCR(多對引子聚合酶連鎖反應) PCR / Multiplex PCR (multiple primer polymerase chain reaction)

PCR係加入2.5μl的10×Ex Taq buffer、1μl的DNA模板、2μl的dNTP、各0.025μl的引子、0.125μl的Ex Taq、2μl的MgCl2、16.88μl的H2O於PCR管進行。多對引子聚合酶連鎖反應係將上述組成更改成各0.1μl的50μM Forward引子3個、Reverse引子3個、16.75μl的H2O進行。反應條件係以95℃熱處理10分鐘後,進行95℃.30秒、50℃.30秒、72℃.30秒之循環30次,最後72℃,7分鐘,使完全地完成延長反應。多對引子聚合酶連鎖反應之煉合(annealing)溫度係以53℃進行。 For PCR, 2.5 μl of 10 × Ex Taq buffer, 1 μl of DNA template, 2 μl of dNTP, 0.025 μl of each primer, 0.125 μl of Ex Taq, 2 μl of MgCl 2 , and 16.88 μl of H 2 O were performed in a PCR tube. The multiple primer polymerase chain reaction was performed by changing the above composition to three 50 μM forward primers, three Reverse primers, and 16.75 μl H 2 O each. The reaction conditions were heat-treated at 95 ° C for 10 minutes, and then performed at 95 ° C. 30 seconds, 50 ° C. 30 seconds, 72 ° C. 30 cycles of 30 seconds, and finally 72 ° C, 7 minutes, to complete the extension reaction completely. The annealing temperature of a plurality of primer polymerase chain reactions was performed at 53 ° C.

(實施例3-2) (Example 3-2)

臨床分離株之分離 Isolation of clinical isolates

自任意選擇之健康人男女7人(男:3人,女:4 人),採取牙菌斑,於Actinomyces選擇培養基(CFAT瓊脂培養基)培養,將所形成之菌落,革蘭氏染色後,藉由顯微鏡觀察,篩選革蘭氏陽性桿菌。 7 healthy men and women from any choice (Male: 3, Female: 4 Human). Plaque was collected and cultured in Actinomyces selection medium (CFAT agar medium). The formed colonies were Gram-stained and then observed under a microscope to screen for Gram-positive bacilli.

自各革蘭氏陽性桿菌,以基因萃取試劑組(sigma)萃取基因,依據實施例3-1進行PCR,使16SrRNA基因上端增幅約500bp。使用於PCR之引起序列如表1所示。 Genes were extracted from each Gram-positive bacterium with a gene extraction reagent set (sigma), and PCR was performed according to Example 3-1 to increase the upper end of the 16SrRNA gene by about 500 bp. The sequences used for PCR are shown in Table 1.

PCR產物係以PCR Clean-Up試劑組(promega)精製,鹽基序列分析係委託外部(股)Macrogen-japan社進行。取得之16SrRNA基因之鹽基序列與GenBank上之資料庫之相同性搜尋而推定菌。上述推定為Actinomyces屬的菌係依據實施例3-1,以多對引子聚合酶連鎖反應使atpA增幅,同樣地委託外部(股)Macrogen-japan社進行鹽基序列分析。使用的引子序列係如表1所示。將取得之鹽基序列與資料庫上的atpA之鹽基序列一同以系統解析,進行種的鑑定,所得之A.naeslundii、A.oris為Actinomyces spp.臨床分離株。 The PCR products were purified using the PCR Clean-Up reagent set (promega), and the analysis of the base sequence was commissioned by an external (stock) Macrogen-japan company. The obtained base sequence of the 16SrRNA gene was searched for the identity with the database on GenBank to estimate the bacteria. According to Example 3-1, the above-mentioned bacterial line of Actinomyces genus was used to increase atpA by a plurality of pairs of primer polymerase chain reactions, and similarly commissioned an external (stock) Macrogen-japan company to perform a salt-based sequence analysis. The primer sequences used are shown in Table 1. The obtained base sequence was systematically analyzed together with the base sequence of atpA on the database for species identification. The obtained A.naeslundii and A.oris were Actinomyces spp. Clinical isolates.

依據上述實施例,自人口腔內進行分離臨床分離株之結果,自7人成功地分離合計9株之Actinomyces臨床分離株(A.naeslundii:4株、A.oris:5株)。進一步對於分離的Actinomyces臨床分離株中的7株,評估水菜冷水萃取物之生物薄膜形成抑制活性時,生物薄膜形成量雖依菌株而異,但水菜冷水萃取物係對於所有的臨床分離株,顯示生物薄膜抑制活性(圖5)。合併圖3的結果時,顯示水菜冷水萃取物即使於人口腔內,顯示生物薄膜形成抑制活性的可能性高。 According to the above examples, the clinical isolates were isolated from the oral cavity of humans, and a total of 9 Actinomyces clinical isolates (A. naeslundii: 4 strains and A.oris: 5 strains) were successfully isolated from 7 people. Further, for 7 of the clinical isolates of Actinomyces isolates, when evaluating the biofilm formation inhibitory activity of cold water extracts of watercress, although the amount of biofilm formation differed by strains, the cold water extracts of watercress showed that for all clinical isolates, Biofilm inhibitory activity (Figure 5). When the results of FIG. 3 are combined, it is shown that the cold water extract of watercress is highly likely to show the activity of inhibiting biofilm formation even in a human oral cavity.

(實施例4) (Example 4)

使用流式處理槽(Flow Cell)之水菜冷水萃取物之生物薄膜抑制評估 Biofilm Inhibition Evaluation of Cold Water Extracts from Water Vegetables Using a Flow Cell

上述實施例係藉由使用96孔盤之靜止系統之評估,顯示水菜冷水萃取物具有Actinomyces naeslundii生物薄膜抑制活性。然而若考慮實際的口腔內時,唾液不斷地分泌,口腔內存在著唾液的流動。因此,因為評估水菜冷水萃取物即使於口腔內是否顯示A.naeslundii生物薄膜抑制活性,所以使用模擬口腔環境之流式處理槽,評估水菜冷水萃取物之A.naeslundii生物薄膜抑制活性。 The above examples were evaluated by a stationary system using a 96-well plate, and showed that cold water extracts of watercress have Actinomyces naeslundii biofilm inhibitory activity. However, when the actual oral cavity is considered, saliva is continuously secreted, and there is a flow of saliva in the oral cavity. Therefore, in order to evaluate whether the cold water extract of aquatic plants showed A.naeslundii biofilm inhibitory activity even in the oral cavity, a flow-type processing tank simulating the oral environment was used to evaluate the A.naeslundii biofilm inhibitory activity of cold water extracts of vegetable.

評估方法 assessment method (實施例4-1)評估菌株 (Example 4-1) Evaluation strain

使用Actinomyces naeslundii ATCC19039株。 Actinomyces naeslundii ATCC19039 strain was used.

(實施例4-2)水菜萃取物之調製 (Example 4-2) Preparation of water vegetable extract

購入市售水菜,以冷凍乾燥調製水菜乾燥葉。以相對於1g之此粉碎的水菜乾燥葉,50ml之去離子蒸餾水的比率,以4℃條件下進行萃取2小時。將藉由吸引過濾及離心除去水菜殘渣之上清液冷凍乾燥,回收水菜萃取物。 A commercially available water dish was purchased, and the dried leaves of the water dish were prepared by freeze-drying. Extraction was performed at 4 ° C. for 2 hours at a ratio of 50 ml of deionized distilled water to 1 g of the crushed hydrophyte dried leaves. The supernatant of the water vegetable residue was removed by suction filtration and centrifugation, and the water vegetable extract was recovered.

(實施例4-3)使用流式處理槽之生物薄膜形成試驗 (Example 4-3) Biofilm formation test using flow processing tank

將A.naeslundii於5ml之BHI培養基培養一晚,離心集菌後,以PBS進行離心洗淨,以BHI培養基調製成O.D.660nm=0.4,將此作為試驗菌液。接種400μl的試驗菌液於流式處理槽艙(ACCFL0001:STOVALL LIFE SCIENCE社),艙的朝向係生物薄膜形成面為下側後,於37℃條件下靜置3小時,使菌附著於薄膜形成面。靜置後,艙的朝向係以生物薄膜形成面為上側,將添加0.25%蔗糖.60mM丁酸之TSB培養基,藉由蠕動幫浦(Peristaltic Pump)以3ml/小時的流速流動下,進行培養48小時,使形成生物薄膜。水菜冷水萃取物之生物薄膜抑制活性係添加水菜冷水萃取物於前述培養基,使最終濃度成為1mg/ml,以同樣地培養後進行評估。 A.naeslundii was cultured in 5 ml of BHI medium overnight, and the bacteria were collected by centrifugation, followed by centrifugation and washing with PBS. The BHI medium was prepared to have an OD of 660 nm = 0.4, and this was used as the test bacterial solution. Inoculate 400 μl of the test bacterial solution in a flow processing tank chamber (ACCFL0001: STOVALL LIFE SCIENCE). After the biofilm forming surface of the chamber is on the lower side, let it stand at 37 ° C for 3 hours to allow the bacteria to adhere to the film. surface. After standing, the orientation of the cabin is based on the biofilm formation surface, and 0.25% sucrose will be added. A 60 mM butyric acid TSB medium was cultured under a peristaltic pump at a flow rate of 3 ml / hour for 48 hours to form a biofilm. The biofilm-inhibiting activity of the cold water extract of watercress is to add the cold water extract of watercress to the aforementioned culture medium so that the final concentration becomes 1 mg / ml, and the evaluation is performed after the same culture.

(實施例4-4)生物薄膜之觀察 (Example 4-4) Observation of biofilm

以去離子蒸餾水洗淨所形成之生物薄膜,藉由LIVE/DEAE BIOFILM VIABILITY KIT(invitrogen社)進行Live/Dead染色後,以共軛焦雷射顯微鏡觀察生物薄 膜。 The formed biofilm was washed with deionized distilled water, and after the Live / Dead staining with LIVE / DEAE BIOFILM VIABILITY KIT (invitrogen), the biofilm was observed with a conjugate coke laser microscope. membrane.

依據上述實施例,評估使用流式處理槽之流動系統條件下之水菜冷水萃取物之生物薄膜形成抑制活性時,水菜冷水萃取物抑制A.naeslundii之生物薄膜形成(圖6、7)。另外,由藉由共軛焦雷射顯微鏡觀察,水菜冷水萃取物添加條件下所形成之生物薄膜係死菌佔有比率減少(圖7)。 According to the above examples, when the biofilm formation inhibitory activity of cold water extracts of cold water extracts under the conditions of a flow system using a flow processing tank was evaluated, the cold water extracts of cold water extracts inhibited the biofilm formation of A.naeslundii (Figures 6 and 7). In addition, the observation by a conjugate coke laser microscope showed that the occupancy ratio of the biofilm-based dead bacteria formed under the condition that the cold-water extract of water vegetable was added (FIG. 7).

更詳細而言,使用流式處理槽之評估中,若添加丁酸時,增加A.naeslundii之生物薄膜形成,該生物薄膜係生菌與死菌相同程度存在。構成生物薄膜之死菌比率係比未添加丁酸時高。於1mg/ml之水菜冷水萃取物存在下,A.naeslundii之生物薄膜形成量受抑制,尤其死菌的附著量減少。因此,顯示水菜冷水萃取物係抑制依賴丁酸之A.naeslundii之生物薄膜形成。 In more detail, in the evaluation using a flow processing tank, if butyric acid is added, the biofilm formation of A.naeslundii is increased, and the biofilm system has the same degree of bacterial and dead bacteria. The ratio of dead bacteria constituting the biofilm is higher than when no butyric acid is added. In the presence of cold water extract of 1 mg / ml water vegetables, the biofilm formation of A.naeslundii was inhibited, especially the amount of dead bacteria attached was reduced. Therefore, it is shown that the cold water extract of Brassica napus inhibits the formation of biofilms of A. naeslundii dependent on butyric acid.

(實施例5) (Example 5)

水菜冷水萃取物之分離區劃 Separation of cold water extracts from water vegetables

(實施例5-1) (Example 5-1)

透析 Dialysis

將水菜冷水萃取物溶解於去離子蒸餾水,以13,000×g,離心10分鐘,回收上清液,放入分離區劃分子量10kDa之透析用纖維素管(as-1),對去離子蒸餾水,於低溫室內進行透析2天。將部份透析內液與外液冷凍乾燥而回 收。 The cold water extract of water vegetable was dissolved in deionized distilled water, centrifuged at 13,000 × g for 10 minutes, and the supernatant was recovered. The cellulose was placed in a dialysis cellulose tube (as-1) with a molecular weight of 10 kDa in a separation zone. Dialysis was performed indoors for 2 days. Freeze-dried part of the inner and outer dialysis fluids Close.

為了如上述推定水菜冷水萃取物之分子量,藉由分離區劃分子量10kDa之透析用纖維素管,透析水菜冷水萃取物,評估透析內液及外液之生物薄膜抑制活性時,透析內液的活性高。顯示活性成分之分子量係10kDa以上(圖8)。 In order to estimate the molecular weight of cold-water extracts of water vegetables as described above, the dialysis of cold-water extracts of water vegetables was evaluated by separating the dialysis cellulose tube with a molecular weight of 10 kDa, and the activity of dialysis internal and external liquids was evaluated. . The molecular weight of the active ingredient was 10 kDa or more (Fig. 8).

(實施例5-2) (Example 5-2)

水菜冷水萃取物之透析內液之離子交換層析 Ion exchange chromatography of dialysis internal fluid of cold water extract

溶解樣品於10mM磷酸鉀緩衝溶液(pH7.4),將離心分離後之上清液,施予DEAE-TOYOPEARL 650M( 1.6×70cm)。以相同的緩衝溶液洗淨後,以0-0.5M NaCl線性梯度沖提,分取各分離部份5ml。另外,所有的操作係以流速1ml/分進行。 The sample was dissolved in a 10 mM potassium phosphate buffer solution (pH 7.4), and the supernatant was centrifuged and administered to DEAE-TOYOPEARL 650M ( 1.6 × 70 cm). After washing with the same buffer solution, it was extracted with a linear gradient of 0-0.5M NaCl, and 5 ml of each separated part was collected. In addition, all operations were performed at a flow rate of 1 ml / min.

藉由陰離子交換層析分離區劃水菜冷水萃取物之透析內液,評估依賴沖提出哪種成分而顯示活性(圖9)。其結果,活性係於蛋白質之第1波峰至第2波峰,依賴蛋白質之沖提模式而顯示活性。由此等顯示活性成分為蛋白質之可能性。 Anion exchange chromatography was used to separate the dialysis fluid from the cold water extract of watercress, and the activity was evaluated depending on which component was extracted (Figure 9). As a result, the activity is in the first peak to the second peak of the protein, and the activity is shown depending on the extraction mode of the protein. The above shows the possibility that the active ingredient is a protein.

(實施例5-3) (Example 5-3)

硫酸銨分離區劃 Division of ammonium sulfate separation

將依據實例5-1而調製之水菜冷水萃取物之透析內液樣品,溶解於PBS,將硫酸銨的濃度階段地提高至30%、 45%、60%、75%,將各濃度之沈澱物,以13,000×g離心15分鐘後回收。將回收沈澱區劃部份,溶解於去離子蒸餾水,透析後冷凍乾燥回收。另外,75%未沈澱區劃部份亦於透析後,冷凍乾燥回收。 A dialysis internal fluid sample of the cold water extract of the water vegetable prepared according to Example 5-1 was dissolved in PBS, and the concentration of ammonium sulfate was gradually increased to 30%, 45%, 60%, 75%, the precipitates of each concentration were recovered by centrifugation at 13,000 × g for 15 minutes. The recovered precipitation division was dissolved in deionized distilled water, and then lyophilized and recovered after dialysis. In addition, 75% of the unprecipitated area was also freeze-dried and recovered after dialysis.

如上所述,生物薄膜形成抑制活性成分若為蛋白質,認為硫酸銨分離區劃有效,藉由硫酸銨分離區劃水菜冷水萃取物之透析內液,評估各濃度之沈澱區劃部份之生物薄膜形成抑制活性(圖10)。可見硫酸銨濃度為45~60%之沈澱區劃部份之生物薄膜形成抑制活性最高。 As mentioned above, if the biofilm formation inhibitory active ingredient is a protein, ammonium sulfate separation is considered effective. The ammonium sulfate separation zone is used to divide the dialysis internal solution of cold water extracts of vegetables, and the biofilm formation inhibitory activity of the precipitation zone at each concentration is evaluated. (Figure 10). It can be seen that the biofilm formation inhibitory activity is highest in the precipitation zone with ammonium sulfate concentration of 45 ~ 60%.

(實施例5-4) (Example 5-4)

水菜冷水萃取物之硫酸銨分離區劃物之離子交換層析 Ion exchange chromatography of ammonium sulfate separation zone of cold water extract

將依據實施例5-3調製之以硫酸銨濃度為45~60%之沈澱區劃部份,依據實施例5-2,藉由離子交換層析分離區劃的結果,可見有2個生物薄膜形成抑制活性波峰(圖11)。 According to Example 5-3, the precipitation division with ammonium sulfate concentration of 45 to 60% was prepared. According to Example 5-2, the results of the separation division by ion exchange chromatography showed that two biofilm formation inhibition Active peak (Figure 11).

(實施例6) (Example 6)

含有成分定量 Contained ingredients

(實施例6-1) (Example 6-1)

蛋白質定量 Protein quantification

蛋白質的定量係使用BCA法進行。 The protein was quantified using the BCA method.

(實施例6-2) (Example 6-2)

糖定量 Sugar ration

糖的定量係使用苯酚-硫酸法進行。 The sugar was quantified using the phenol-sulfuric acid method.

(實施例6-3) (Example 6-3)

多酚定量 Polyphenol quantification

多酚的定量係使用Folin-ciocalteu法進行。 Polyphenols were quantified using the Folin-ciocalteu method.

上述,關於精製,將水菜冷水萃取物藉由透析、硫酸銨分離區劃及陰離子交換層析而分離區劃的結果,歸納如表2所示。隨著精製階段進展,每重量的比活性變高,活性成分的精製進展中。另外,離子交換層析之活性區劃部份之含有成分係80%以上為蛋白質,顯示活性成分為蛋白質之可能性。 As mentioned above, Table 2 summarizes the results of refining the separation results of cold water extracts of watercress by dialysis, ammonium sulfate separation, and anion exchange chromatography. As the refining stage progresses, the specific activity per weight becomes higher, and the refining of the active ingredient is progressing. In addition, more than 80% of the content of the active zone of ion exchange chromatography is a protein, indicating that the active ingredient is a protein.

(實施例7) (Example 7)

摻混水菜萃取物口香糖之生物薄膜形成抑制活性評估 Evaluation of Biofilm Formation Inhibitory Activity of Chewing Gum Blended with Hydroponic Extract

(實施例7-1) (Example 7-1)

摻混水菜之口香糖之製作 Production of chewing gum mixed with water vegetables

以第3組成製成摻混水菜冷水萃取物口香糖。 Based on the third composition, a cold water extract chewing gum with mixed vegetables is prepared.

BFI-01:加入水菜冷水萃取物,混煉12分鐘。 BFI-01: Add cold water extract of water vegetable and mix for 12 minutes.

BFI-02:混煉12分鐘後,加入水菜冷水萃取物,之後,混煉3分鐘程度。 BFI-02: After 12 minutes of kneading, add cold water extract of water vegetable, and then knead for about 3 minutes.

(實施例7-2) (Example 7-2)

口香糖萃取液之調製 Preparation of chewing gum extract

於5g之口香糖,加入25ml之加溫成37℃之PBS,於研缽內搗潰5分鐘,進行萃取,以1,100×g離心15分鐘,回收其上清液,以滅菌濾器(0.2μm)進行滅菌處理物作為口香糖萃取液。 To 5 g of chewing gum, add 25 ml of PBS warmed to 37 ° C, mash in a mortar for 5 minutes, extract, centrifuge at 1,100 × g for 15 minutes, recover the supernatant, and perform a sterilizing filter (0.2 μm). The sterilized product was used as a gum extract.

(實施例7-3) (Example 7-3)

口香糖萃取液之生物薄膜形成抑制活性 Biofilm formation inhibitory activity of chewing gum extract

使用96孔微量滴定盤進行。於各孔中添加50μl的添加1%蔗糖之4×TSB培養基、100μl的口香糖萃取液、20μl的125mM丁酸、20μl的試驗菌懸浮液、10μl的PBS,於37℃,5%CO2之條件下,進行培養16~20小時。生物薄膜形成量的定量係依據實施例2-2進行。 Performed using a 96-well microtiter plate. Add 50 μl of 4 × TSB medium with 1% sucrose, 100 μl of chewing gum extract, 20 μl of 125 mM butyric acid, 20 μl of test bacteria suspension, 10 μl of PBS to each well at 37 ° C, 5% CO 2 Then, incubate for 16-20 hours. The amount of biofilm formation was quantified in accordance with Example 2-2.

(實施例7-4) (Example 7-4)

水菜萃取物自口香糖之溶出率評估 Evaluation of dissolution rate of water vegetable extract from chewing gum

進行280nm之波長之吸光度(Abs280nm)測定,由下述計算式評估水菜萃取物之溶出率。 The absorbance (Abs 280 nm) of a wavelength of 280 nm was measured, and the dissolution rate of the water vegetable extract was evaluated from the following calculation formula.

(A1)使水菜萃取物,以2000ppm之濃度溶解於對照口香糖萃取液者之Abs280nm (A1) Abs 280nm of a water-soluble vegetable extract dissolved in a control chewing gum extract at a concentration of 2000 ppm

(A2)摻混水菜冷水萃取物口香糖萃取液之Abs280nm (A2) Abs280nm of chewing gum extract with cold water extract

(A3)對照口香糖之Abs280nm (A3) Abs280nm of control chewing gum

溶出率(%)=((A2-A3)/(A1-A3))×100 Dissolution rate (%) = ((A2-A3) / (A1-A3)) × 100

依據上述實施例,關於摻混水菜冷水萃取物口香糖萃取液之生物薄膜形成抑制活性,進行檢討時,摻混水菜冷水萃取物口香糖萃取液係抑制A.naeslundii之生物薄膜形成(圖12)。另外,亦未見摻混水菜冷水萃取物於口香糖所引起之活性降低。另外,水菜冷水萃取物之溶出率係BFI-01為83.0%,BFI-02為85.7%。 According to the above embodiment, regarding the biofilm formation inhibitory activity of chewing gum cold water extract blended with cold water extract, when reviewing, chewing gum cold liquid extract mixed with cold water extract inhibited the biofilm formation of A.naeslundii (Figure 12). In addition, there was no decrease in the activity caused by mixing cold water extracts of hydroponics with chewing gum. In addition, the dissolution rate of cold water extracts of water vegetables was 83.0% for BFI-01 and 85.7% for BFI-02.

水菜冷水萃取物係對Actinomyces臨床株,亦顯示生物薄膜形成抑制活性,另外,使用羥磷石灰上及流式處理 槽之評估中,因為抑制生物薄膜形成,所以顯示水菜冷水萃取物即使於人口腔內仍顯示生物薄膜形成抑制活性之可能性。 The cold water extract of Actinidia esculenta showed clinical inhibitory activity against Actinomyces clinical strains. In addition, it was treated with hydroxyphosphate lime and flow-through. In the evaluation of the tank, because the biofilm formation is inhibited, the possibility that the cold-water extract of water vegetable shows the biofilm formation inhibitory activity even in the human oral cavity is shown.

依據水菜冷水萃取物之活性成分之分離區劃,顯示蛋白質為活性成分之可能性。另一方面,資料雖未顯示,但認為因為未見有BSA或乳蛋白質製劑之生物薄膜抑制活性,所以不是所有蛋白質皆見有活性,而是水菜冷水萃取物中所含蛋白質可見有特異的Actinomyces生物薄膜形成抑制活性。 According to the separation of active ingredients in cold water extracts of water vegetables, the possibility of proteins as active ingredients is shown. On the other hand, although the data is not shown, it is believed that because no biofilm inhibitory activity of BSA or milk protein preparations is seen, not all proteins are active, but specific Actinomyces are seen in the proteins contained in cold water extracts of water vegetables. Biofilm formation inhibitory activity.

水菜冷水萃取物見有Actinomyces生物薄膜形成抑制活性,即使對Actinomyces臨床分離株,亦見有效果。水菜冷水萃取物於羥磷石灰上,以及使用流式處理槽之評估中,亦顯示生物薄膜形成抑制活性,顯示於人口腔內顯示活性的可能性。另外,摻混水菜冷水萃取物口香糖顯示A.naeslundii生物薄膜形成抑制活性。 Actinomyces biofilm formation inhibitory activity was found in cold water extracts of watercress, and it was effective even on clinical isolates of Actinomyces. The cold water extract of watercress on hydroxyphosphate lime, and the evaluation using a flow treatment tank, also showed the biofilm formation inhibitory activity, showing the possibility of showing activity in the human mouth. In addition, chewing gum with cold water extract of hydroponics showed A.naeslundii biofilm formation inhibitory activity.

將水菜冷水萃取物藉由透析、硫酸銨分離區劃、陰離子交換層析分離區劃時,顯示活性成分係分子量為10kDa以上之蛋白質。 When the cold-water extract of water vegetable was separated by dialysis, ammonium sulfate separation, and anion exchange chromatography, the active ingredient was a protein with a molecular weight of 10 kDa or more.

接著,以常法製造上述口香糖以外之製品之含有本發明之含有水菜冷水萃取物之生物薄膜形成抑制劑之漱口劑、牙膏、口臭用噴劑、口含錠、硬糖、錠果、軟糖、飲料。以下係表示此等之配方。另外,本發明品之範圍並非受此等限制者。 Next, a mouthwash, a toothpaste, a bad breath spray, a lozenge, a hard candy, a lozenge, a softener containing the biofilm formation inhibitor containing the cold-water extract of the present invention and a product other than the above-mentioned chewing gum are manufactured by a conventional method. Sugar, drinks. The following shows these formulations. In addition, the scope of the present invention is not limited by these.

(實施例8) (Example 8)

依據下述配方製造漱口劑。 Mouthwash was manufactured according to the following formulation.

(實施例9) (Example 9)

依據下述配方製造牙膏。 Toothpaste was manufactured according to the following formulation.

(實施例10) (Example 10)

依據下述配方製造口臭用噴劑。 A bad breath spray was produced according to the following formulation.

(實施例11) (Example 11)

依據下述配方製造口含錠。 Oral tablets were produced according to the following formulation.

(實施例12) (Example 12)

依據下述配方製造硬糖。 Hard candies were produced according to the following recipe.

(實施例13) (Example 13)

依據下述配方製造錠果。 Ingots were produced according to the following recipe.

(實施例14) (Example 14)

依據下述配方製造軟糖。 Fudge was produced according to the following recipe.

(實施例15) (Example 15)

依據下述配方製造飲料。 A beverage was manufactured according to the following recipe.

〔產業上利用性〕 [Industrial availability]

本發明之含有水菜冷水萃取物之口腔用組成物因為具有與傳統的對牙周病原性細菌之抗菌劑不同的作用之顯示生物薄膜形成抑制作用之牙週病預防作用,所以為嶄新觀 點之牙周病預防劑。因此,與已存在的抗菌劑等比較,認為有耐性菌出現風險低等優點,可應用於各種製品。 The oral composition containing the cold-water extract of hydroponic vegetable of the present invention has a new view because it has a different effect from the conventional antibacterial agent for periodontal pathogenic bacteria and has a periodontal disease prevention effect showing an inhibitory effect on biofilm formation. Point of periodontal disease preventive. Therefore, compared with existing antibacterial agents and the like, it is considered that they have advantages such as a low risk of occurrence of resistant bacteria, and can be applied to various products.

Claims (9)

一種口腔用組成物,其特徵係含有在4℃下萃取之水菜冷水萃取物,將該水菜冷水萃取物之活性成分分離區劃之結果,活性成分為分子量10kDa以上之成分,且活性區劃部份所含有之成分的80%以上為蛋白質。A composition for oral cavity, which is characterized by containing cold water extract of cold water extract extracted at 4 ° C, and separating and dividing the active ingredients of the cold water extract of cold water extract. The active ingredient is a component with a molecular weight of 10 kDa or more, and the active zone More than 80% of the contained ingredients are protein. 一種生物薄膜形成抑制劑,其特徵係含有在4℃下萃取之水菜冷水萃取物,將該水菜冷水萃取物之活性成分分離區劃之結果,活性成分為分子量10kDa以上之成分,且活性區劃部份所含有之成分的80%以上為蛋白質。A biofilm formation inhibitor, which is characterized by containing cold water extract of cold water extract extracted at 4 ° C, and separating and dividing active ingredients of the cold water extract of cold water extract. The active ingredient is a component with a molecular weight of 10 kDa or more, and the active zone More than 80% of the contained ingredients are protein. 如申請專利範圍第2項之生物薄膜形成抑制劑,其中該生物薄膜形成抑制劑為牙周病生物薄膜抑制劑。For example, the biofilm formation inhibitor of the second patent application range, wherein the biofilm formation inhibitor is a periodontal disease biofilm inhibitor. 如申請專利範圍第2項之生物薄膜形成抑制劑,其中該生物薄膜形成抑制劑為酸衍生生物薄膜抑制劑。For example, the biofilm formation inhibitor of the second patent application range, wherein the biofilm formation inhibitor is an acid-derived biofilm inhibitor. 一種漱口劑,其特徵係含有如申請專利範圍第1項之口腔用組成物。A mouthwash, which is characterized by containing the composition for oral cavity as described in claim 1 of the scope of patent application. 一種牙膏劑,其特徵係含有如申請專利範圍第1項之口腔用組成物。A toothpaste is characterized by containing the composition for oral cavity as described in the first patent application. 一種吸入劑,其特徵係含有如申請專利範圍第1項之口腔用組成物。An inhalant comprising an oral composition as described in claim 1 of the scope of patent application. 一種口含錠劑,其特徵係含有如申請專利範圍第1項之口腔用組成物。An oral lozenge is characterized in that it contains an oral composition as described in item 1 of the patent application. 一種食品,其特徵係含有如申請專利範圍第1項之口腔用組成物。A food product characterized by containing an oral composition as described in claim 1 of the scope of patent application.
TW102132187A 2013-02-01 2013-09-06 Oral composition TWI620576B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013018728 2013-02-01

Publications (2)

Publication Number Publication Date
TW201431565A TW201431565A (en) 2014-08-16
TWI620576B true TWI620576B (en) 2018-04-11

Family

ID=51261580

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102132187A TWI620576B (en) 2013-02-01 2013-09-06 Oral composition

Country Status (5)

Country Link
JP (2) JP6300736B2 (en)
KR (1) KR20150114521A (en)
CN (1) CN104968327A (en)
TW (1) TWI620576B (en)
WO (1) WO2014118829A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6300736B2 (en) * 2013-02-01 2018-03-28 株式会社ロッテ Oral composition
TWI702224B (en) * 2018-11-30 2020-08-21 國立成功大學 Aptamers of surface proteins of periodontal pathogens and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102198407A (en) * 2010-03-24 2011-09-28 索尼公司 Positive ion exchanger and method for removing heavy metal ion in waste water
CN102317299A (en) * 2009-02-13 2012-01-11 株式会社钟化 Plant extract containing antifreeze substance and method for producing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10259136A (en) * 1997-03-17 1998-09-29 Taiyo Koryo Kk Virus proliferation suppressor and pharmaceutical composition containing the same virus proliferation suppressor
JP4948044B2 (en) * 2006-06-02 2012-06-06 三栄源エフ・エフ・アイ株式会社 Plaque formation inhibitor or anti-cariogenic agent
JP2009027926A (en) * 2007-07-24 2009-02-12 Sunstar Inc Powdery beverage containing plant as raw material
JP6016343B2 (en) * 2011-09-08 2016-10-26 株式会社ロッテ Oral composition
JP6300736B2 (en) * 2013-02-01 2018-03-28 株式会社ロッテ Oral composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317299A (en) * 2009-02-13 2012-01-11 株式会社钟化 Plant extract containing antifreeze substance and method for producing same
CN102198407A (en) * 2010-03-24 2011-09-28 索尼公司 Positive ion exchanger and method for removing heavy metal ion in waste water

Also Published As

Publication number Publication date
JP6300736B2 (en) 2018-03-28
JP2018127455A (en) 2018-08-16
WO2014118829A1 (en) 2014-08-07
CN104968327A (en) 2015-10-07
JP6564084B2 (en) 2019-08-21
KR20150114521A (en) 2015-10-12
TW201431565A (en) 2014-08-16
JPWO2014118829A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
Ferrazzano et al. In vitro antibacterial activity of pomegranate juice and peel extracts on cariogenic bacteria
KR101900992B1 (en) Prophylactic or therapeutic agent for oral diseases
TWI736911B (en) Novel cutibacterium granulosum strain, and composition for preventing or treating acne comprising the strain or its culture
WO2003099110A2 (en) Herbs and herbal combinations useful for the treatment of microbial infections
JP3988953B2 (en) Antimicrobial active substance DM0507 and use thereof
JP5906011B2 (en) Oral composition
FR2916634A1 (en) Synergistic combination, useful e.g. as regulating agent of microbial flora of skin and to prepare cosmetic or pharmaceutical composition to treat oily or mixed skin, of fructo-oligosaccharides and inducer of antimicrobial peptide
WO2018025204A1 (en) Lactic bacteria and the use thereof for the preventive, inhibitory and/or reductive treatment of the formation of bacterial biofilms
Roh et al. Antimicrobial activity of Korean propolis extracts on oral pathogenic microorganisms
TWI620576B (en) Oral composition
JP6679202B2 (en) Type IV allergy composition
KR102095339B1 (en) Novel lactobacillus reuteri and composition for preventing or treating periodontal diseases comprising the same
Sajadi et al. Antibacterial effect of two herbal extracts on the level of salivary Streptococcus mutans in children
JP6293177B2 (en) Oral composition
KR101017447B1 (en) Antibacterial composition and oral composition for preventing caries containing the extract of fennel
El Naggar et al. Effect of Propolis and Pomegranate Extract Mouthwashes on Taste Alteration, Salivary pH and Antibacterial Activity in High Caries Risk Patients: A Randomized Control Trial.
KR20190142510A (en) Composition for Preventing or Treating Periodontal Disease Comprising Scutellaria Extract treated by Aspergillus niger as Active Ingredient
KR102511133B1 (en) Composition for Inhibiting Biofilm Formation Comprising Extracts of Coptis chinensis
Soekanto et al. Chewing gum containing propolis wax from Apis mellifera bees for prevention of dental caries disease
KR102022006B1 (en) Composition for Preventing or Treating Periodontal Disease Comprising Scutellaria Extract treated by Enzyme Isolated from Aspergillus niger as Active Ingredient
Shafiei In Vitro Study on the Effect of Plant Extract Mixture and Its Individual Constituents Towards Single-And Dual-Species Biofilms
Chismirina et al. The Antibacterial Effects of Syzygium Cumini Fruit Mouthwash Against Streptococcus mutans as an Agent of Dental Caries
JP6918529B2 (en) Oral composition
Fagera Evaluation of Antimicrobial Activity of Honey on Human Oral Cavity Microbiota
Alnasrawy et al. Isolation, characterization and estimation of ellagic acid activity against Porphyromonas gingivalis isolated from adult periodontitis patients in Kerbala City